France

News from aidsmap

• French researchers report 14 patients in 'remission' after controlling HIV for over 4 years off treatment

  The search for a cure
  Gus Cairns | 16 March 2013

  Two weeks ago, the announcement that a baby had been ‘functionally cured’ of HIV disease with the use of very early antiretroviral therapy (ART) caused great excitement at the start of the Conference on ...

• Are we underestimating the proportion of virally-suppressed patients in the US?

  Infectiousness and treatment as prevention
  Gus Cairns | 15 March 2013

  Several presentations at the recent 20th Conference on Retroviruses and Opportunistic Infections in Atlanta suggest that previous estimates of the proportion of people with HIV in the USA who are on antiretroviral ...

• French studies report real-world data on use of telaprevir and boceprevir in people with HIV and hepatitis C co-infection

  Hepatitis C treatment
  Liz Highleyman | 05 March 2013

  Adding boceprevir or telaprevir to interferon-based therapy showed promising indications of efficacy and acceptable safety for difficult-to-treat HIV/HCV co-infected prior non-responders in a pair of French studies presented yesterday at the 20th Conference on Retroviruses and ...

• Co-infection with hepatitis B or C is a risk factor for reduced bone mineral density among women with HIV

  Bone problems
  Michael Carter | 28 January 2013

  Co-infection with hepatitis B or C is associated with reduced bone mineral density (BMD) in women living with HIV, French investigators report in the online edition of the Journal of Acquired Immune ...

• Young people know less about HIV and are less trustful of condoms, French survey finds

  Safer sex
  Gus Cairns | 10 January 2013

  The first survey for six years of attitudes to HIV and sexual risk behaviour among the general public in France has found that young people are less frightened of AIDS than they used ...

• Hepatitis C patients with cirrhosis respond well to boceprevir or telaprevir with careful monitoring

  New and experimental hepatitis C treatment
  Liz Highleyman | 05 December 2012

  Real-world experience in the French early-access CUPIC cohort shows that hepatitis C patients with advanced liver damage can achieve good response to interferon-based triple-therapy including boceprevir (Victrelis) or telaprevir (Incivo), researchers reported ...

• Telaprevir and VX-222 pair well in interferon-free regimen, VX-135 on the horizon

  New and experimental hepatitis C treatment
  Liz Highleyman | 03 December 2012

  An all-oral regimen of telaprevir, VX-222 and ribavirin for 12 weeks was generally well-tolerated and produced sustained virological response in approximately 70% of previously untreated chronic hepatitis C patients, according to findings from ...

• Traditional risk factors predict neurocognitive impairment in people with HIV

  Neurological and cognitive problems
  Michael Carter | 31 October 2012

  Neurocognitive impairment in people with HIV – loss of memory, poor concentration and declining mental ability – is most likely to be happening for the same reasons as in the ...